Genomic Health, Inc. was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock was down 4.5% in the past one-month time frame.
The move came after the company announced that it is likely to produce results from eight Oncotype DX studies at the 2017 American Society of Clinical Oncology Annual Meeting. The study will represent data across multiple types of tumor that includes invasive breast, ductal carcinoma in situ, prostate as well as renal cancers.
The company has seen five negative estimate revisions in the past one month, while its Zacks Consensus Estimate has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Genomic Health currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
A better-ranked stock in the Medical - Biomedical and Genetics industry is VIVUS, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is GHDX going up? Or down? Predict to see what others think: Up or Down
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Image: Bigstock
Genomic Health (GHDX) Looks Good: Stock Adds 5.2% in Session
Genomic Health, Inc. was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock was down 4.5% in the past one-month time frame.
The move came after the company announced that it is likely to produce results from eight Oncotype DX studies at the 2017 American Society of Clinical Oncology Annual Meeting. The study will represent data across multiple types of tumor that includes invasive breast, ductal carcinoma in situ, prostate as well as renal cancers.
The company has seen five negative estimate revisions in the past one month, while its Zacks Consensus Estimate has also moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Genomic Health currently has a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Genomic Health, Inc. Price
Genomic Health, Inc. Price | Genomic Health, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is VIVUS, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is GHDX going up? Or down? Predict to see what others think: Up or Down
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>